We describe a "high-performance" liquid-chromatographic procedure for measuring 3-methoxy-4-hydroxymandelic acid (vanillylmandelic acid) in urine. The compound is quantitatively extracted from urine by use of an automated system, including an anion-exchange resin. After elution from the resin and concentration by air drying, the urine extract is chromatographed on an octyl silica column, with use of a buffered mobile phase. To overcome interference from other organic acids in the extract, the column effluent is reacted with periodate in an analytical system to oxidize the analyte and internal standard to products that absorb at 360 nm. We evaluated the procedure for precision, linearity, analytical recovery, interfering substances, and correlation with an established procedure. The combination of a preliminary resin extraction, a liquid-chromatographic separation, and a periodate oxidative monitor results in a rapid, specific method that can be adapted for use in the clinical laboratory. gas-chromatographic (7,8), and liquid-chromatographic (9, 10) procedures for VMA have been reported. We have developed a "high-performance" liquid chromatographic procedure for VMA, which obviates the need for extensive pretreatment of urine and which eliminates interferences reported in other assays (11). We use a preliminary anion-exchange extraction of urine as well as a novel detector for continuously monitoring periodate oxidation products. Received Aug. 14, 1978; accepted Jan. 9, 1979. Presented at the 30th national AACC meeting in San Francisco. GUn. Chem. 24, 1051 (1978), abstract no. 311.
mandelic acid; iso-VMA, 3-hydroxy-4-methoxymandelic acid.
Liquid chromatograph:
Model 601 (Perkin-ElmerCorp., Norwalk, CT 06856) equipped with 4.6mm X 25cm column, which is packed with octyl silica (DuPont) and maintained at 55 #{176}C in the column oven. We used a precolumn (4.6 mm X 4 cm), which we packed with octyl-decyl groups bonded to glass beads (Whatman Inc., Clifton, NJ 07014).
Periodate oxidation monitor: Figure 1 shows a diagram of the continuous-flow reaction system. A Model 3 proportioning
pump (Technicon Instruments
Corp., Tarrytown, NY 10591) removes a portion of the column effluent and immediately segments it with air (to maintain resolution of separated compounds), mixes it with the periodate oxidation reagent, and pumps the stream into a heating bath. After the stream emerges from the bath, excess periodate is reduced, and the stream is debubbled and aspirated through the detector cuvette, where it is monitored at 360 nm by a Coleman LC-55 spectrophotometer (Perkin-Elmer), with full-scale recorder deflection set at 0.01 absorbance. We use a flow cell (Hellma Cells, Inc., Jamaica, NY 11424) with a 1-cm light path and an 80-zL total volume. We used this flow cell in place of the smaller volume, high-pressure flow cell with which the spectrophotometer was equipped. 
Reagents

Procedure
Extraction:
Add 2 mL ofworking standard solution or urine to the reservoirs above the resin in the disposable columns, followed by 2 mL of extraction buffer containing the internal standard solution. Place the columns in the DuPont Prep I extractor.
During the 30-mm program, the VMA and iso-VMA are extracted from the samples, the resin in each column is washed with 1.3 mL of distilled water, the compounds of interest are eluted with 1.3 mL of the formic acid/acetone eluting solvent, and finally the eluates are concentrated to dryness in a stream of air, at 60 #{176}C.
Chromatography:
Dissolve the dried extracts in 0.5 mL of 0.5 mol/L sodium phosphate, pH 3.0, and inject 30-50 L into the chromatograph.
The mobile phase contains sodium phosphate (50 mmol/L, pH 3.0), which has been filtered through a O.65-m filter before use. The normal operating pressure of the column is about 3.45 MPa (500 psi).
Detection: The continuous-flow system used as the periodate oxidation monitor is diagrammed in Figure 1 .
Additional Materials and Procedures
Urine samples: Urines used for the correlation and normal-value study were collected in glass bottles containing 12 mL of HC1 (6 mol/L). Samples not assayed within 24 h were stored frozen. Urines used for precision studies included a lyophilized urine pool, as well as a patient's urine that was divided into aliquots and frozen.
Manual extraction:
A manual batch-extraction was also evaluated for recovery of VMA. The extraction involved addition of 2 mL of a VMA standard solution and 2 mL of extraction buffer containing internal standard to 80mg of BioHad AG MP-1 resin. The sample, buffer, and resin are mixed for 10 mm and, after centrifuging, the aqueous layer is aspirated off. To elute the VMA and iso-VMA, we add 1 mL of formic acid-acetone eluting solvent.The eluate is air dried, reconstituted in 0.5 mL of phosphate buffer (0.5 mol/L, pH 3.0), and injected into the liquid chromatograph.
Ultraviolet
detection:
The results with our periodate monitor detector are compared to direct ultraviolet detector results. For ultraviolet detection, the total column effluent flows directly to the Coleman LC-55 spectrophotometer through steel tubing (0.015 inch i.d.). The high-pressure flow is used.
Results
The chromatograms of urine extracts shown in Figure 2 demonstrate our results with two types of chromatographic detection systems. In Figure 2a the column effluent was monitored at 230 nm by a direct ultraviolet detection system.
A peak that is consistent with the retention time for VMA is pointed out in the chromatogram. The peak is only partly resolved from other interfering peaks. In similar chromatograms of other urine extracts, the VMA was completely unresolvable from other ultraviolet-absorbing compounds. Figure 2b shows a chromatograph of a urine extract for which the periodate oxidation monitor diagrammed in Figure 1 was used. This chromatogram shows a single major peak. For pure VMA standards as well as for supplemented urine samples this peak is identifiable as VMA. In chromatograms of other urine extracts, additional peaks have been observed. These peaks are resolved from VMA, as we will show in our interfering substance studies. We used the periodate oxidation monitor throughout the rest of our development studies. Figure 3a shows a chromatogram of a urine extract to which the internal standard, iso-VMA, was added before the extraction. The VMA and iso-VMA have retention times of 8.0 and 9.9 mm, respectively. To determine whether the detection of VMA and iso-VMA is based upon the oxidation of these compounds to products that absorb at 360 nm, we replaced the periodate reagent with distilled water. As seen in Figure  3b the oxidation products of VMA and iso-VMA were no longer detected under these conditions. the same method used for urine samples, and peak-height ratios were used for the quantitation. With VMA concentration on the x axis, the regression equation was y = 0.19x -0.18 (r = .996). Intra-assay precision was determined by analysis of 10 samples of a lyophilized control urine and a frozen urine pool (frozen in aliquots). The mean for the lyophilized urine was 5.2 mg/L (SD, 0.07; CV, 4.1%), for the frozen pool 6.6 mg/L (SD, 0.11; CV, 5.2%). Interassay precision was determined by measuring aliquots of these same urines on eight separate days. The mean for the lyophilized urine was 5.0 mg/L (SD, 0.28; CV, 5.7%), for the frozen pool 6.9 mgIL (SD, 0.42; CV, 6.1%). The frozen pool was found to be stable for at least three months.
We performed analytical-recovery studies, using aqueous standards, to determine the absolute recovery of VMA and the internal standard. Peak heights for extracted and unextracted samples were compared. For the automated extraction system, complete recovery of VMA and iso-VMA was observed (Table 1) . When these experiments were performed by the manual batch extraction, analytical recovery of VMA and iso-VMA ranged from 31 to 37%. Although the recovery was less for the manual batch extraction, the relative extraction efficiency of VMA and iso-VMA was comparable to the results with the automated extraction. Using the automated extraction system, we studied the recovery of VMA from urine. The recoveries shown in Table 2 indicate that VMA can be measured in aqueous solution or urine, with equivalent results.
Possible interfering substances were studied. A series of potentially interfering compounds has been chromatographed without prior extraction. Table 3 lists retention times for compounds detected by our periodate oxidation monitor, none of which interfere with our determination of VMA. In addition to the selectivity of the chromatographic separation, aminecontaining compounds are eliminated by the preliminary extraction with anion-exchange resin. We found, for instance, that the catecholamines and metanephrines at a concentration of 50 mgfL are undetected by our high-performance chromatographic system after anion-exchange extraction. At least two of the organic acids included in the interference study have been identified in urine from patients. In several urine extracts, 5-hydroxyindoleacetic acid has been seen. In the chromatogram from one patient (Figure 4 ) with a urinary salicylate exceeding 400 mg/24 h, we identified several additional peaks. One peak was consistent with gentisic acid, a metabolite of salicylate. Other compounds, including 5-hydroxymndoleacetic acid, were also found.
We were also interested in the potential interference of endogenous iso-VMA. To determine if any endogenous iso-VMA is detectable in our assay system, we assayed urines without adding iso-VMA as internal standard. No endogenous iso-VMA was detected in urine from nine laboratory volunteers and from 15 patients, including one patient with pheochromocytoma. 
Discussion
High-performance liquid chromatography is potentially a powerful technique for the separation and quantitation of compounds in complex samples. There has been limited success, however, in the measurement of urinary VMA by liquid chromatographic procedures. Workers using either anionexchange (9) or reversed-phase (12) columns have found urinary compounds with chromatographic retention times very close to that for VMA. Using an ultraviolet detector, we found many compounds that interfere with the quantitative determination of urinary VMA. In this study we have developed a more specific detector system. We have applied the technologies of post-column derivatization and continuousflow analysis to develop a chemical reaction detector that is simple and versatile. The only equipment required is a proportioning pump and a spectrophotometer equipped with a flow cell. The column eluate is proportioned off and immediately air segmented. This sample segmentation minimizes loss in separation efficiency. Subsequent reagent additions, mixing, and heating are performed by continuous-flow technology. We have demonstrated the specificity of this detector system by a comparison with results with an ultraviolet-detector.
The detection-system chemistry is based upon the oxidation of VMA to van illin, which absorbs at 360 nm, the same reaction used in many spectrophotometric methods (3, 4) . This reaction is not completely specific for VMA. There are various dietary compounds, drugs, and metabolites that either absorb at 360 nm or that form periodate oxidation products that absorb at 360 nm. In an attempt to eliminate interference by these compounds, the spectrophotometric procedures include several extraction steps as well as a blank analysis in which periodate is not included. In our procedure we perform one initial extraction followed by the liquid-chromatographic analysis. The assay requires no sample blank, because interfering substances that are not removed by the initial extraction are separated from VMA by the chromatographic system.
The procedure therefore appears to be specific for VMA. An anion-exchange extraction system has also been used. In most other procedures, VMA is removed from urine by liquid-liquid extractions with organic solvents. We have found, however, that VMA can be extracted from urine conveniently and with high efficiency by anion-exchange resin. We use an automated extraction system that utilizes centrifugal force and anion-exchange columns to extract VMA from urine. With 2-mL samples of urine, the system can extract 12 samples during 30 minutes. Analytical recovery studies indicate excellent efficiency and reproducibility of the extraction system.
We chose iso-VMA as the internal standard because it is extracted with high efficiency by our anion-exchange system, because it can be chromatographically separated from VMA, and because it can be oxidized and measured by our detector. We were concerned with reports that iso-VMA may be produced in vivo by a minor pathway of catecholamine metabolism (12), but we have been unable to detect it in urine from laboratory volunteers or patients. This may be due to the higher sensitivity of the assay for VMA vs. iso-VMA, and to the relatively low concentration of iso-VMA reported in urine. It remains possible that endogenous iso-VMA in the urine of certain patients may cause interference in this procedure or in any procedure in which periodate oxidation is used. Many other drugs, metabolites, and dietary compounds reportedly interfere with VMA assays (11) . In studying the effect of these compounds on our assay, we have found that the combination of an anion-exchange extraction, chromatographic separation, and periodate oxidation monitor eliminates these potential interferences.
The assay does not require blank analysis or dietary restrictions before sample collection. We find the assay to be sensitive and specific for urinary VMA. The periodate oxidation mohitor can be easily adapted to high-performance liquid-chromatography now in use. The periodate oxidation monitor is only one application of effluent monitoringby continuous-flow analysis. We hope that other applications will be developed and will increase the usefulness of high-performance liquid chromatography in the clinical laboratory.
